Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 1/20 | 0.61 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | MC5R | P33032 | 1/20 | 0.39 |
| ▸ | MC3R | P41968 | 1/20 | 0.39 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL759516 | 0.93 | CCR6 (0.66) | CCR6PAX8ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL7535687 | 0.91 | CCR6 (0.64) | CCR6PAX8ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL4173945 | 0.86 | CCR6 (0.59) | CCR6PAX8ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL2076709 | 0.86 | CCR6 (0.59) | CCR6PAX8SLC6A2SLC6A3KMT2A | |
| SCHEMBL15355992 | 0.86 | CCR6 (0.59) | CCR6PAX8ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL18057683 | 0.86 | CCR6 (0.61) | CCR6PAX8ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL10181395 | 0.86 | CCR6 (0.61) | CCR6PAX8ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL2076254 | 0.85 | CCR6 (0.62) | CCR6PAX8L3MBTL1 | |
| SCHEMBL16585962 | 0.85 | CCR6 (0.60) | CCR6PAX8ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL5557184 | 0.85 | CCR6 (0.58) | CCR6PAX8ALDH1A1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017432-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | Reiley Pharmaceuticals, Inc. | 2022-01-20 | — | — | US | disclosed |
| US-9850183-B2 | Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging | Reiley Pharmaceuticals, Inc. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20150374858-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | Reiley Pharmaceuticals, Inc. | 2015-12-31 | — | — | US | disclosed |
| WO-2015200187-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | Reiley Pharmaceuticals, Inc. (US) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017432-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | PTGES3, PTGES, HPGDS | CCR6 137/4885PAX8 3350/4885ALDH1A1 626/4885 |
| US-20150374858-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | PTGES3, PTGES, HPGDS | CCR6 137/4885PAX8 3350/4885ALDH1A1 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.